Janus Henderson Group PLC Sutro Biopharma, Inc. Transaction History

Janus Henderson Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$7.78 - $15.31 $1.71 Million - $3.37 Million	-220,045 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$14.25 - $23.53 $46,056 - $76,048	3,232 Added 1.49%	220,045 $3.28 Million
Q3 2021 Nov 16, 2021	BUY	$16.88 - $22.38 $371,241 - $492,203	21,993 Added 11.29%	216,813 $4.1 Million
Q2 2021 Aug 16, 2021	BUY	$18.03 - $23.82 $583,234 - $770,529	32,348 Added 19.91%	194,820 $3.63 Million
Q1 2021 May 17, 2021	SELL	$20.29 - $27.54 $414,747 - $562,945	-20,441 Reduced 11.18%	162,472 $3.7 Million
Q4 2020 Feb 16, 2021	BUY	$10.16 - $23.98 $273,263 - $644,966	26,896 Added 17.24%	182,913 $3.96 Million
Q3 2020 Nov 16, 2020	SELL	$7.44 - $13.15 $52,742 - $93,220	-7,089 Reduced 4.35%	156,017 $1.57 Million
Q2 2020 Aug 14, 2020	SELL	$7.24 - $11.05 $37,213 - $56,797	-5,140 Reduced 3.06%	163,106 $1.26 Million
Q1 2020 May 14, 2020	BUY	$6.19 - $12.16 $874,758 - $1.72 Million	141,318 Added 524.8%	168,246 $1.71 Million
Q4 2019 Feb 18, 2020	BUY	$8.15 - $11.39 $219,463 - $306,709	26,928 New	26,928 $296,000

137

62.4M

77.1K

31.4K

Ticker STRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,161,500
Market Cap $140M
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.